Patents Assigned to Merck
  • Patent number: 10780092
    Abstract: The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R1, R3, R4a, R5a, R5b, R6, and the subscript t are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceuticals for this purpose.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: September 22, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Alan Whitehead, Olga Ornoski, Subharekha Raghavan, Raphaelle Berger, Joie Garfunkle, Zhiqiang Yang, Gang Ji, Falong Jiang, Jianmin Fu
  • Publication number: 20200289493
    Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 17, 2020
    Applicants: TESARO, Inc., MERCK SHARP & DOHME B.V.
    Inventors: Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson
  • Publication number: 20200291347
    Abstract: The present invention relates to methods for performing cell culture by using a solid cell culture media form prepared by a 3D printing process.
    Type: Application
    Filed: October 24, 2018
    Publication date: September 17, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Werner STOCKUM, Charlotte LINDHARDT
  • Publication number: 20200289406
    Abstract: The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes. The drug product can be used for the treatment or prophylaxis of infection by HIV or for the treatment, prophylaxis, or delay in the onset of AIDS (acquired immunodeficiency syndrome) or ARC (AIDS related complex).
    Type: Application
    Filed: March 19, 2018
    Publication date: September 17, 2020
    Applicants: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B. V.
    Inventors: Sachin Mittal, Irina Kazakevich, Himanshu Bhattacharjee, Peter Bakker, Luke Schenck, David J. Goldfarb, Amitava Mitra, Donna Carroll, Nazia Khawaja
  • Publication number: 20200291299
    Abstract: The invention relates to a polymerisable LC material comprising at least one monoreactive mesogenic compound, at least one di- or multireactive mesogenic compound and pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate). Furthermore, the present invention relates also to a method for its preparation, a polymer film with improved thermal durability obtainable from the corresponding polymerisable LC material, to a method of preparation of such polymer film, and to the use of such polymer film and said polymerisable LC material for optical, electro-optical, decorative or security devices.
    Type: Application
    Filed: February 7, 2017
    Publication date: September 17, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Stephen MULCAHY, lain GARDINER, Jack BRADFORD
  • Publication number: 20200289761
    Abstract: A syringe is provided herein for injecting medication into a patient, the syringe including a tubular barrel having opposing inner and outer surfaces, an open proximal end, and a distal end having a wall extending thereacross. An opening is defined in the wall with a needle mount extending distally from the wall about the opening. A first panel extends radially outwardly from the outer surface of the barrel, the first panel having opposing first and second faces. Further, a first scale including a series of spaced-apart first graduations is disposed on the first face of the first panel. Advantageously, with the subject invention, a syringe may be provided having a planar portion, in addition to its barrel, with graduations marked thereon for improved viewing by a practitioner in determining a proper dose amount.
    Type: Application
    Filed: November 26, 2018
    Publication date: September 17, 2020
    Applicants: Merck Sharp & Dohme Pharmaceutical Industrial and Commercial Societe Anonyme, MSD IT Global Innovation Center S.R.O.
    Inventors: Georgios Errikos GRIGOREAS, Ashley Marie POLHEMUS
  • Publication number: 20200290996
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: October 4, 2018
    Publication date: September 17, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Catherine M. White, Abdelghani Achab, Indu T. Bharathan, Xavier Fradera, Yongxin Han, Derun Li, Jongwon Lim, Kun Liu, Meredeth Ann McGowan, Nunzio Sciammetta, Wensheng Yu, Hongjun Zhang, Hua Zhou
  • Publication number: 20200291298
    Abstract: Disclosed are a liquid-crystalline medium which contains at least one compound of formula IA, and in addition at least one compound of formula CC-n-V and/or CC-V-V1, where the percentage proportion of the compound(s) of formula IA is greater than or equal to the percentage proportion of CC-n-V, and/or the percentage proportion of the compound(s) of formula IA is greater than the percentage proportion of CC-V-V1, where the percentage proportion is based on the liquid-crystalline medium, and the use thereof in active-matrix displays, in particular based on the VA, PSA, PVA, PS-VA, SS-VA, SA-VA, PA-VA, PALC, FFS, PS-FFS, PS-IPS or IPS effect.
    Type: Application
    Filed: June 2, 2020
    Publication date: September 17, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Harald HIRSCHMANN, Martina WINDHORST, Volker REIFFENRATH
  • Patent number: 10774061
    Abstract: The invention relates to a liquid-crystalline medium, preferably having a nematic phase and dielectric anisotropy of 0.5 or more, which comprises one or more compounds of formula S in which denotes and to the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type, and to the use of the compounds of formula S for the improvement of the transmission and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: September 15, 2020
    Assignee: Merck Patent GmbH
    Inventors: Atsutaka Manabe, Constanze Brocke, Brigitte Schuler, Ramin Tavakoli
  • Patent number: 10772888
    Abstract: Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: September 15, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Majid Mahjour, Feng Li, Decheng Ma, Sutthilug Sotthivirat
  • Patent number: 10772947
    Abstract: The invention provides human papillomavirus (HPV) antigen formulations which show increased antigen stability. More specifically, the invention provides stable HPV formulations comprising HPV virus-like particles (VLPs) bound to an aluminum salt adjuvant and further comprise a combination of sucrose and mannitol. The vaccine formulations of the invention are stable following freeze-thaw and freeze-drying. Also provided are lyophilized and frozen HPV vaccine formulations comprising HPV VLPs of at least one HPV type adsorbed onto an aluminum salt adjuvant, sucrose, and mannitol. Methods of making the stable vaccine formulations of the invention are also provided.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: September 15, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ramesh V. Chintala, Akhilesh Bhambhani
  • Patent number: 10774263
    Abstract: A liquid-crystalline medium, preferably having a nematic phase and exhibiting a dielectric anisotropy of 0.5 or more, which contains compounds of formula B and formula S in which denotes denotes the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, displays of this type which contain a liquid-crystalline medium of this type, and the use of the compounds of formula S for the improvement of the transmission and/or response times of a liquid-crystalline medium which contains one or more additional mesogenic compounds.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: September 15, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Atsutaka Manabe, Constanze Brocke, Herbert Plach
  • Patent number: 10774362
    Abstract: Sample preparation unit, preferably for sterility testing: a housing body including at least two ports adapted to serve as fluid inlet and/or fluid outlet, a membrane support, and a lid part such that a membrane chamber is defined adjacent said membrane support. One of at least two ports is arranged so as to allow a fluid transfer to/from a first volume of the membrane chamber at a position upstream of a membrane to be placed on the membrane support, and the other ports arranged to allow fluid transfer to/from a second volume of said membrane chamber at a position downstream of a membrane to be placed on said membrane support. A movable part is provided on housing body such that the movable part and housing body are movable relative to each other, selectively interrupting/establishing fluid transfer between at least one of two ports and the membrane chamber.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: September 15, 2020
    Assignee: Merck Patent GmbH
    Inventors: Anne Baumstummler, Marie Pressel, Sandra Laborde, David Lehmann, Gael Waiche
  • Publication number: 20200281913
    Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Application
    Filed: July 12, 2018
    Publication date: September 10, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Alexander Pasternak, Shuzhi Dong, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Dexi Yang, Xin Gu, Jinlong Jiang, Li Xiao
  • Publication number: 20200282040
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these N serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.
    Type: Application
    Filed: September 4, 2018
    Publication date: September 10, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
  • Publication number: 20200282070
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.
    Type: Application
    Filed: September 4, 2018
    Publication date: September 10, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
  • Publication number: 20200283894
    Abstract: Methods of forming metal-containing films by atomic layer deposition are provided. The methods include delivering a metal-containing complex, a purge gas, and a co-reactant to a first substrate under sufficient conditions such that the metal-containing film selectively grows on at least a portion of the first substrate.
    Type: Application
    Filed: June 22, 2018
    Publication date: September 10, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Jean-Sébastien LEHN, Charles DEZELAH, Jacob WOODRUFF
  • Publication number: 20200283443
    Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.
    Type: Application
    Filed: February 20, 2020
    Publication date: September 10, 2020
    Applicant: MERCK & CIE
    Inventors: Rudolf MOSER, Viola GROEHN, Thomas EGGER, Thomas AMMANN
  • Patent number: 10768132
    Abstract: The present patent application relates to a device (1) for measuring the conductivity of a liquid, which comprises a measuring chamber for containing a sampling volume to be irradiated with UV rays formed in a hydraulic body (4) which comprises an inlet channel for feeding the measuring chamber with liquid to be measured and an outlet channel for removing the measured liquid from the measuring chamber, the inlet channel and the outlet channel emerging on either side beyond a surface exposed to the UV rays, such that only the sampling volume contained in the measuring chamber is irradiated. The present patent application is also directed towards a use of such a device and to a purification system comprising such a device.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: September 8, 2020
    Assignee: Merck Patent GmbH
    Inventors: Pascal Rajagopalan, Yves Gaignet, Celine Le Ninivin Glipa
  • Patent number: D896648
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: September 22, 2020
    Assignee: Merck Sharp & Dohme, Corp.
    Inventors: Tinh Nguyen-DeMary, Raymond K. Seto